Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
boston
clinical trials
drugs
fda
national top stories
roche
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
biopharma
biotech
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
deals
detroit blog main
detroit top stories
dna sequencing
duchenne
entrectinib
europe blog main
europe top stories
express scripts
foundation medicine
givosiran
indiana blog main
indiana top stories
josh bilenker
keytruda
larotrectinib
licensing
loxo oncology
m&a
What
fda
3
×
medicine
3
×
second
3
×
approval
drug
rna
ago
alnylam
approved
betting
billion
biopharma
cancer
deal
deeper
dna
duchenne
fingerprint
gene
genetic
going
historic
indicated
interference
matter
nd
new
nod
oks
pharmaceuticals
puts
quick
recently
rnai
roche
sarepta
seek
speedy
swiss
targets
Language
unset
Current search:
second
×
fda
×
medicine
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug